发明名称 DIFFERENTIAL METHYLATION LEVEL OF CPG LOCI THAT ARE DETERMINATIVE OF KIDNEY CANCER
摘要 The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of kidney cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal kidney tissue, as set forth.
申请公布号 US2015218643(A1) 申请公布日期 2015.08.06
申请号 US201414174542 申请日期 2014.02.06
申请人 Lasseigne Brittany N.;Myers Richard M.;Absher Devin;Brooks James D. 发明人 Lasseigne Brittany N.;Myers Richard M.;Absher Devin;Brooks James D.
分类号 C12Q1/68 主分类号 C12Q1/68
代理机构 代理人
主权项 1. A method for determining the presence or absence of kidney cancer in an individual, the method comprising: a. identifying an individual in need of the prevention or treatment of kidney cancer; b. obtaining a biological sample from the individual and isolating the DNA therefrom; c. determining the methylation level of at least one cytosine within a DNA region in a sample from the individual where the DNA region is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 4, 6, 7, 8, 11, 12, 13, 14, 17, 20, 21, 22, 23, and 24; and d. comparing the methylation level of the at least one cytosine to a threshold value for the at least one cytosine, wherein the threshold value distinguishes between individuals with and without kidney cancer, wherein the comparison of the methylation level to the threshold value is predictive of the presence or absence of kidney cancer in the individual.
地址 Huntsville AL US